Microbion enrols first patient in Phase IIa orthopedic infection trial of MBN-101

19th June 2016 (Last Updated June 19th, 2016 18:30)

US-based biopharmaceutical company Microbion has enrolled the first patient in its Phase IIa trial of MBN-101 to treat orthopedic implant-related infections.

US-based biopharmaceutical company Microbion has enrolled the first patient in its Phase IIa trial of MBN-101 to treat orthopedic implant-related infections.

MBN-101 is the company's bismuth-thiol class lead drug candidate, which is being developed to combat against difficult to treat infections.

Its anti-bacterial properties render it effective against a wide range of pathogens, including multiple priority pathogens or superbugs.

MBN-101 has also exhibited its ability to eradicate microbial biofilms.

"When treating difficult infections associated with orthopedic implants, which are increasingly common, physicians urgently need more effective treatments."

The randomised, placebo-controlled, dose ranging Phase IIa trial will enrol patients with implant-related orthopedic infections.

The trial is intended to assess the safety and efficacy of MBN-101 in improving patient outcomes who are afflicted with orthopedic implant related infections.

Perelman School of Medicine, University of Pennsylvania orthopaedic surgery associate professor orthopaedic trauma division chief and principal investigator of study Dr Samir Mehta said: "When treating difficult infections associated with orthopedic implants, which are increasingly common, physicians urgently need more effective treatments.

"We are eager to evaluate MBN-101 as a potentially important new treatment for patients with orthopedic infections, as it represents a new therapeutic approach that benefits from recent advances in our understanding of bacteria."

MBN-101 has been awarded the qualified infectious disease product (QIDP) designation by the US Food and Drug Administration (FDA) indicated for post-surgical orthopedic implant infections, and was also granted Fast Track status for this indication by the FDA last year.